ADAPY

distress 7/10 · high distress / dilution risk

$0.03-2%today-92% from 52w high

adaptimmune.com272 employeesFounded 2008Abingdon, United KingdomBiotechnology

Lead: synovial sarcoma and MRCLS

Revenue

$21M

Liquidity

$26M

Runway

0.1 yrs

Shares 1y

Price & events

-18.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.7%

-28.7%

-16.2%

+185.0%

-18.6%

-90.2%

-97.7%

-99.2%

-99.5%

All

Overview

Market Cap: $45.32M
Enterprise Value: $44.94M
Volume: 69
52 Week Range: $0.00 – $0.35
Total Shares: 1.59B
Float Shares: 263.34M
Short %: 14.34%
% Held by Insiders: 0.63%
% Held by Institutions: 0.00%
RVOL: 0.00x
Beta: 0.89

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 3

Q4 2025regulatory submissionFiled (NDA/BLA)lete-cel · Initiate rolling BLA submissionSEC 8-K
2025-07-27partnershipTECELRA, lete-cel, afami-cel, uza-cel · Asset purchase agreement with US WorldMeds for sale of cell therapies.SEC 8-K
November 16, 2024conferencedata presentationsecondaryPhase 2lete-cel · Primary analysis data from IGNYTE-ESO trial presented at CTOS 2024.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 1,590,309,546 · 1 offerings/1y · 0 PIPEs

2025-11-14EFFECTshelf_effective
2025-11-13424B3offering
2025-07-288-Kmaterial_agreement
2025-04-18S-3shelf_registration
2025-03-248-Kmaterial_agreement
2024-11-13SC 13G/Astrategic_stake
2024-09-238-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2025-07-29HC Wainwright & Co.Buy → Neutral
2025-06-26MizuhoOutperform → Neutral
2025-05-14BarclaysUnderweight
2025-05-14Wells FargoEqual-Weight

Competitors — synovial sarcoma and MRCLS

none identified